Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abaxis management shuffle

This article was originally published in The Gray Sheet

Executive Summary

Firm names President and CEO Clint Severson as chairman of the board, replacing Abaxis co-founder Gary Stroy. Severson has been key to increasing revenue while reducing operational costs for the past seven quarters, the company says. Jim Canfield, former VP-marketing and sales at competitor Idexx Laboratories, joins Abaxis as VP-domestic marketing. Canfield replaces Vladimir Ostoich, who returns to his original position as VP-engineering. Chief Financial Officer and VP-finance Ting Lu is stepping down at the end of the month and will be replaced in the interim by Controller Reba Witwer. Other new appointments include Robert Milder as VP-operations; Larry Reynolds (VP-marketing and sales, Pacific Rim and Latin America) and Diane Oates (VP-regulatory affairs/quality systems)...

You may also be interested in...

COVID-19 Vaccine Could Cost As Little As $10 A Dose, Says Janssen

Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.

Austria’s Apeiron To Attack COVID-19 At Its Entry Point

Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark. 


Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics

Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts